Pharma major Lupin Limited (Lupin) announced today the launch of Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin's alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).
Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, are the generic equivalent of Prograf® Capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc., and are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant, liver transplant, and heart transplant, and in pediatric patients receiving allogeneic liver transplants, in combination with other immunosuppressants.
Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg (RLD: Prograf®) had an annual sales of approximately USD 303 million in the U.S. (IQVIA MAT September 2020).
Shares of LUPIN LTD. was last trading in BSE at Rs.895.2 as compared to the previous close of Rs. 883.95. The total number of shares traded during the day was 116991 in over 3401 trades.
The stock hit an intraday high of Rs. 898.35 and intraday low of 879.4. The net turnover during the day was Rs. 104241247.